Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Multiple Myeloma 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 2Cyclophosphamide 2siltuximab 1ruxolitinib 1ricolinostat 1repotrectinib 1pralsetinib 1ponatinib 1pomalidomide 1pamiparib 1fludarabine 1ficlatuzumab 1enzalutamide 1blinatumomab 1Taxes 1Radiation 1Pemetrexed 1Paclitaxel 1Gefitinib 1Drug Therapy 1Dexamethasone 1Cisplatin 1CPI-0610 1Bortezomib 1Biopsy 1Bevacizumab 1Bendamustine Hydrochloride 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Histologic Type × siltuximab × Clear all
NCT00841191 2014-05-14

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Centocor, Inc.

Phase 1/2 Completed
84 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Neoplasms by Histologic Type, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡